Patient 28: A fatal case of mirtazapine ingestion

Author: Daniele Di Corcia
Date: 15/06/2011



64 year old
Weight 85 kg
Height 167 cm


Psychiatric treatment
Chronic depression

Adverse Event Resulted In:


2011-06-15T10:08:30 - Daniele Di Corcia



Depression is a common psychiatric disease, affecting about 20% of people during their lifetime. Severe depression is also a major risk factor for suicide, and up to 15% of the patients hospitalized for depression eventually commit suicide(1). In order to treat these common mental illness, several antidepressants drugs are daily prescribed by physicians. The use of antidepressants has substantially increased worldwide during the past two decades and several new antidepressant drugs have been introduced, gradually replacing tricyclic antidepressants (TCAs), such as amitriptyline,clomipramine, doxepine and imipramine, which have been available since the 1960s. The new generation of antidepressants is designed on the basis of molecule targeting, with focus on serotonine level control. Drugs such as citalopram, fluoxetine, paroxetine and sertraline, acting as selective serotonin reuptake inhibitors, have become increasingly popular for the treatment of depression (2). Other antidepressant drugs include the monoamino-oxidase inhibitor moclobemide, and other mixed-uptake inhibitors (mirtazapine, nefazodone and venlafaxine). Ingestion of TCAs is still an important cause of suicidal death, as serious poisoning from TCAs lead to cardiac disturbances, respiratory depression, metabolic acidosis, convulsion and coma. Even if SSRIs are considered to be less toxic than the TCAs (3), numerous case reports have shown that the newer antidepressants may also cause severe intoxication (4).
Among the antidepressants, Mirtazapine is a tetracyclic piperazinoazepine compound, structurally related to mianserin, which has been used since 1994 as an antidepressant. Mirtazapine is a strong α2 antagonist, enhancing noradrenergic and serotonergic neurotransmission, without inhibiting the serotonin re-uptake (Figure 1). Daily doses for adults are normally in the range of 15-45 mg. The oral bioavailability is approximately 50% (5). Adverse effects associated with mirtazapine therapy include somnolence, dizziness, agitation, hypertension and loss of appetite. Overdosage may cause disorientation, drowsiness and tachycardia (Mirtazapine Side Effects)

Link Figure

Figure 1

Mirtazapine - Wikipedia

Mirtazapine - Adverse Event Reports

Case History


A 64-year-old woman (weight 85 kg, height 167 cm) with a previous history of chronic depression was found dead on the kitchen floor of her apartment. She had attempted to commit suicide in the year 2000. Since then, she was under psychiatric treatment. On the table next to her, many packaging of pharmaceutical drugs, suggesting the occurrence of drug-related suicidal death. Specifically, the police seized: 4 boxes of Mirtazapina EG® 30 mg (mirtazapine) containing seven empty blister packs, originally corresponding to 105 tablets. It was not known whether the woman had started consuming this pack in a previous time, so it was not possible to estimate the amount of drug possibly ingested by the victim the day of her death. No letters nor explanation of her act were found in the apartment.
The death was reported to the Public Prosecutor’s office which took jurisdiction of the case. At the autopsy, the decedent did not show any specific pathology and appeared well-nourished. Internal examination presented no evidence of any trauma to account for her death. Therefore, our laboratory received the responsibility to determine whether massive drug assumption could be taken into account as the cause of the death. The specimen sampled during the autopsy included heart blood, urine and gastric content.

Results And Discussion


The presence of mirtazapine was confirmed by LC-MS/MS in all specimens.
The heart blood concentration of mirtazapine was 20.3 mg/L. In order to interpret this finding, some considerations are needed. In eight postmortem cases in which mirtazapine was identified but did not contribute significantly to the cause of death, the mirtazapine concentration in heart blood was found to be approximately equal to the one present in peripheral blood, indicating that postmortem redistribution was not a factor to be taken into account in evaluating the postmortem blood concentrations (6). Moreover, several mirtazapine metabolites are known to have some pharmacological activity but they are not believed to significantly contribute to the overall effects of the drug, due to their low plasma concentrations (7). Thus, the pharmacological level of mirtazapine is generally expressed by its parent drug concentration. The serum therapeutic concentration of mirtazapine ranges from 0.02 to 0.1 mg/L (8), but no published data are available about its toxic concentration. In a single fatal case in which mirtazapine was the only ingested drug, the postmortem blood concentration was found at 2.7 mg/L (9). In the case reported here, the mirtazapine blood concentration is much higher than the expected therapeutic level, so there are good reasons to presume that a toxic level may have been reached.



The fatal case reported in the present study, involving the intake of mirtazapine, suggests that the synergic pharmacological effects of this drug is likely to account for the decease. The agreement between the authoptic examination executed by forensic pathologists and the toxicological findings presented here are consistent with the suicidal hypothesis beyond any reasonable doubt.

TIAFT - The International Association of Forensic Toxicologists

TIAFT was founded in London April 21, 1963. The founding meeting elected Dr. E.C.G. Clarke (UK) as President, Dr. Alan S. Curry (UK) as Secretary, Dr. Ian Holden (UK) as Treasurer and Dr. Fred Rieders (USA) as Newsletter Editor. The first newsletter was edited in November 1963 by Rieders, and from the very beginning it bore the name "Bulletin of the International Association of Forensic Toxicologists". It was a 3-page A4 size blue spirit duplicated leaflet which contained four case notes. The analytical methods relied much on TLC, spectrophotometry and spot tests. The first note was by L.W. Bradford (USA) giving advice on how to calibrate UV spectro-photometers with mercury vapour.
Nowadays TIAFT groups over 1400 members from all regions of the world who are actively engaged in analytical toxicology or allied areas with the aims of this association are to promote cooperation and coordination of efforts among members and to encourage research in forensic toxicology. TIAFT members come from the police force, medical examiners and coroners' laboratories, horseracing and sports doping laboratories, hospitals, departments of legal medicine, pharmacology, pharmacy and toxicology.

Drugs Abuse is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products. Find helpful tools, wallet size personal medication records, mobile applications and more.

Database of clinical evidence of treatment with drugs

The TRIP Database is a clinical search tool designed to allow health professionals to rapidly identify the highest quality clinical evidence for clinical practice.


The European Bioinformatics Institute (EBI) is an academic research institute located on the Wellcome Trust Genome Campus in Hinxton near Cambridge (UK). Our Mission is To provide freely available data and bioinformatics services to all facets of the scientific community in ways that promote scientific progress.


The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information. The database contains 6829 drug entries including 1435 FDA-approved small molecule drugs, 134 FDA-approved biotech (protein/peptide) drugs, 83 nutraceuticals and 5210 experimental drugs. Additionally, 4438 non-redundant protein (i.e. drug target/enzyme/transporter/carrier) sequences are linked to these drug entries. Each DrugCard entry contains more than 150 data fields with half of the information being devoted to drug/chemical data and the other half devoted to drug target or protein data.


The Diseases Database is a cross-referenced index of human disease, medications, symptoms, signs, abnormal investigation findings etc. This site provides a medical textbook-like index and search portal covering areas.


1. D.N. Juurlink, M.M. Mamdani, A.Kopp and D.A. Redelmeier, The risk of suicide with selective serotonin reuptake inhibitors in the elderly, Am. J. Psychiatry, 163:813-821 (2006)
2. E. Kringlen, S. Torgersen, V. Cramer, A Norwegian psychiatric epidemiological study, Am J Psychiatry, 158:1091–1098 (2001)
3. D.J. Pounder and G.R. Jones. Postmortem drug redistribution—a toxicological nightmare. Forensic Sci. Int. 45: 253–263 (1990)
4. M. Reis, T. Aamo, J. Ahlner and H. Druid, Reference concentrations of antidepressants. A compilation of postmortem and therapeutic levels, J. Anal. Toxicol., 31:254-264 (2007)
5. R.C. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 7th ed., Biomedical Publications, Foster City, CA (2004)
6. K.A. Moore, B. Levine, M.L. Smith, S. Saki, J. Schames, J.E. Smialek, Tissue distribution of mirtazapine (Remeron) in postmortem cases, J. Anal. Toxicol, 23(6):541-543 (1999)
7. Physicians’ desk reference, Medical Economics Company, Montvale, NJ (1997)
8. E.G.C. Clarke, Clarke’s Isolation and Identification of Drugs in Pharmaceutical, Body Fluids and Post-mortem Materials, 3rd ed., The pharmaceutical Press, London, 2005
9. M.D. Robertson, P.S. Ng and S.B. Gore, Death due to mirtazapine (Remeron) toxicity. Presented at the annual meeting of the Society of Forensic Toxicologists, Puerto Rico, October 12, 1999

AddThis Social Bookmark Button